Guidelines are inconsistent regarding annual QuantiFERON® TB Gold (QFT) tests in children taking biologics for dermatological conditions, and there is limited research on seroconversion, especially in regions with high tuberculosis (TB) prevalence. A retrospective review of pediatric patients taking biologic treatment for psoriasis or hidradenitis suppurativa (HS) who had one baseline and at least one follow-up QFT test was conducted to assess for seroconversion during treatment. Thirty-two patients were included, with no instances of seroconversion. These findings suggest that routine annual TB rescreening for pediatric patients taking biologic therapy for dermatologic conditions may not be necessary without additional TB exposure risks or symptomatology.

中文翻译：

---

一项回顾性研究分析了纽约市学术中心接受生物治疗的儿童银屑病和化脓性汗腺炎患者的 QuantiFERON TB-gold 检测，未出现血清转化

关于因皮肤病而服用生物制剂的儿童的年度 QuantiFERON® TB Gold (QFT) 检测指南并不一致，而且关于血清转化的研究有限，特别是在结核病 (TB) 患病率较高的地区。对接受生物治疗银屑病或化脓性汗腺炎 (HS) 的儿科患者进行回顾性评价，这些患者具有一项基线和至少一项后续 QFT 测试，以评估治疗期间的血清转化情况。包括 32 名患者，没有出现血清转化的情况。这些发现表明，如果没有额外的结核病暴露风险或症状，可能没有必要对因皮肤病而接受生物治疗的儿科患者进行每年例行的结核病再筛查。